Recent meta-analyses and retrospective studies have reported that the use of SGLT-2 inhibitors in type 2 DM patients with or without HF, as well as in type 2 DM patients with HF, reduces the incidence rate of AF, atrial flutter, and other cardiovascular events [16–19]. This evidence concerns the gene SLC5A2 and hydrops fetalis.